Best 3 Blue Chip Stocks to Buy After a Market Pullback -- Including Microsoft (MSFT) Stock

Microsoft, Becton Dickinson, and Clorox are highlighted as attractively priced blue-chip ideas, with Microsoft trading at 22x forward earnings and yielding 0.9%, Becton Dickinson at 11.7x forward earnings with a 2.8% dividend and 9% total shareholder yield, and Clorox at 13x forward earnings with a 5.1% yield. The piece emphasizes defensive income, share buybacks, and long-term durability rather than a near-term catalyst. It is bullish in tone but is largely stock-picking commentary, so the likely market impact is limited.

Analysis

The clean read-through is not “cheap blue chips,” but a duration trade: the market is paying up for visible near-term growth while discounting self-funding compounders that can keep buying back stock and lifting per-share value even in a slower macro. MSFT is the only one here where AI capex skepticism could create a better entry, because the business mix has enough recurring cash generation to absorb a multi-year infrastructure buildout; if management shows capex plateauing while Azure monetization keeps accelerating, multiple compression should reverse fast. The second-order effect is that suppliers tied to enterprise software and cloud infrastructure may be more exposed to any pause than the platform itself.

BDX is the more underappreciated defensive growth name: its demand profile is less about headline healthcare growth and more about procedural normalization, hospital utilization, and device replacement cycles. The real upside is operating leverage from tuck-in acquisitions and mix improvement, not top-line surprise; that makes it a slower but more durable compounder, especially if risk assets wobble and investors rotate into cash-flow stability. The hidden risk is that reimbursement pressure or procurement consolidation can delay margin expansion even when unit volumes look fine.

CLX is primarily a margin-recovery story with a built-in yield floor. The market is implicitly assuming the company’s cost actions will be sufficient to offset input pressure, but the cleaner setup is that consumer-staples private-label pressure never fully materializes when brand trust remains intact; if that holds, the stock can re-rate before earnings visibly inflect. The contrarian point is that the best risk/reward may already be behind the most obvious “safe income” buyers, so the upside comes from a faster-than-expected efficiency reset rather than dividend support alone.

Key Decisions for Investors

• Go long MSFT on weakness over the next 2-6 weeks; target a re-rating back toward its historical growth premium if AI capex concerns stop widening. Use a staged entry because the main risk is another quarter of heavy spend without commensurate cloud monetization.
• Buy BDX as a 6-12 month defensive compounder; preferred structure is long stock versus a basket of higher-multiple medtech names to capture relative resilience if rates stay volatile. Risk/reward improves if the market starts rewarding recurring revenue and shareholder yield over headline growth.
• For CLX, consider a small long position or call spread into the next 1-2 earnings cycles; the thesis is operating margin recovery plus high dividend support. Stop if cost inflation re-accelerates or private-label share gains show up in channel checks.
• Pair trade: long MSFT / short a basket of large-cap AI capex-heavy beneficiaries with weaker current cash conversion, for 3-6 months. The trade monetizes the market’s distinction between monetized AI and AI spending.
• If looking for income with less downside beta, prefer BDX over CLX; CLX has more margin volatility and is more exposed to commodity input shocks. Hold CLX only if dividend yield is the primary objective and you can tolerate a slower recovery.